Quantcast

Latest The City of London Migraine Clinic Stories

2010-11-30 15:10:56

American Heart Association rapid access journal report Women with a history of migraine headache with aura (transient neurological symptoms, mostly visual impairments) are at increased risk of stroke. However, according to new research reported in Circulation: Journal of the American Heart Association stroke events in women with migraine with aura are more likely to have mild or no disability compared to those without migraine. In a new analysis of the Women's Health Study involving 27,852...

2010-11-08 06:00:00

MOUNTAIN VIEW, Calif., Nov. 8, 2010 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today reported successful results from a thorough QT trial of its investigational LEVADEX(TM) orally inhaled migraine therapy. The trial evaluated the potential of a supra-therapeutic dose to cause an increase in the QT interval. Results of the trial showed that a supra-therapeutic dose of LEVADEX does not increase QTc intervals. LEVADEX is a novel orally inhaled migraine therapy that...

2010-10-29 06:00:00

MOUNTAIN VIEW, Calif., Oct. 29 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced new data from the FREEDOM-301 Phase 3 trial of its investigational LEVADEX(TM) orally inhaled migraine therapy showing low recurrence rates with LEVADEX. Eight additional analyses from the LEVADEX program also will be presented during the 2010 European Headache and Migraine Trust International Congress (EHMTIC) in Nice, France. Physicians commonly use the term recurrence to...

2010-10-29 01:00:00

CHICAGO, Oct. 29 /PRNewswire-USNewswire/ -- New data presented today at The 2010 European Headache and Migraine Trust International Congress (EHMTIC) shows that persons with chronic migraine (headache on greater than or equal to 15 days per month) are much more likely to have annual household incomes below $30,000 than those with episodic migraine (headache on < 15 days per month). This difference in household income may be attributable to the greater adverse headache impact in the...

2010-10-20 07:00:00

MOUNTAIN VIEW, Calif., Oct. 20 /PRNewswire-FirstCall/ --MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the Company will present nine analyses relating to its LEVADEX(TM) orally inhaled migraine therapy product candidate, including analysis from the FREEDOM-301 Phase 3 trial, at the 2010 European Headache and Migraine Trust International Congress (EHMTIC) in Nice, France. EHMTIC is a biennial congress of the Migraine Trust and the European Headache Federation for...

2010-09-22 09:48:10

(Ivanhoe Newswire) "“ Migraines come on suddenly and sharply, and most medicines aren't effective enough to stop the pain completely. This study found that giving Aspirin to patients admitted to the hospital for severe migraines through an IV is safe and effective in stopping migraines. "Intravenous Aspirin is not readily available in the United States and only on a 'named patient' basis in the United Kingdom, while it is more generally used in other parts of Europe," Peter J. Goadsby,...

f96a90f6a2e3b6e8b843058d1c075ad71
2010-09-22 08:30:00

An inexpensive, hundred-year-old therapy for pain "“ aspirin "“ is effective in high doses for the treatment of severe headache and migraine caused by drug withdrawal, according to a new study by researchers with the UCSF Headache Center.  Study participants were administered aspirin through an IV and 25 percent of the time they reported a significant reduction in pain "“ three points on the 10-point pain scale.  (A difference of three points downgrades a headache...

2010-09-20 23:20:51

A new study shows that aspirin, given intravenously (IV), may be a safe and effective option for people hospitalized for severe headache or migraine, undergoing medication withdrawal. The research will be published in the September 21, 2010, issue of Neurology®, the medical journal of the American Academy of Neurology. "Intravenous aspirin is not readily available in the United States and only on a 'named patient' basis in the United Kingdom, while it is more generally used...

2010-09-08 06:05:00

MOUNTAIN VIEW, Calif., Sept. 8 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that all non-asthmatic patients and a subset of asthmatic patients have completed 12 months of treatment in the open-label safety trial of LEVADEX(TM). In addition, the Company has completed patient treatment in a thorough QT trial, the last trial necessary to support a New Drug Application (NDA) for LEVADEX. At this time, all patients have been enrolled in the Company's...

2010-09-02 12:17:40

Psychological migraine treatment gives sufferers a confidence boost in their ability to self-manage their symptoms For severe migraine sufferers, psychological treatments build on the benefits of drug therapy, according to a new study1 by Elizabeth Seng and Dr. Kenneth Holroyd from Ohio University in the US. Their comparison of the effects of various treatment combinations for severe migraine "“ drug therapy with or without behavioral management "“ shows that those patients...


Word of the Day
ween
  • To think; to imagine; to fancy.
  • To be of opinion; have the notion; think; imagine; suppose.
The word 'ween' comes from Middle English wene, from Old English wēn, wēna ("hope, weening, expectation"), from Proto-Germanic *wēniz, *wēnōn (“hope, expectation”), from Proto-Indo-European *wen- (“to strive, love, want, reach, win”).
Related